BOOK
Current Management of Hepatitis C Virus, An Issue of Clinics in Liver Disease, E-Book
(2016)
Additional Information
Book Details
Abstract
Clinical information about Hepatitis C is quickly outdated, so Dr. Poordad has assembled expert authors to provide state-of-the-art clinjcal reviews for hepatologists. This issue is uniquely organized to present articles based on therapeutic regimens for certain types of patients:
Regimens for the Treatment-Naïve Patient; Regimens for Treatment of the Interferon-Failure Patient; Regimens for DAA Failure Patients; Regimens for the Cirrhotic Patient; Regimens for the Peri-Transplant Patient; Regimens for the HIV-Co-Infected Patient; and Next-generation Regimens: The Future of HCV Therapy. This presentation will be very clinically relevant for the practicing hepatologist.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Current Management of\rHepatitis C Virus | i | ||
| Copyright | ii | ||
| Contributors | iii | ||
| CONSULTING EDITOR | iii | ||
| EDITOR | iii | ||
| AUTHORS | iii | ||
| Contents | v | ||
| Preface: Hepatitis C Therapy: Simple for the Patient, not so Simple for the Clinician | v | ||
| Evaluation of Hepatitis C Patients in the Direct-Acting Antiviral Era | v | ||
| Meet the Classes of Directly Acting Antiviral Agents: Strengths and Weaknesses | v | ||
| Regimens for the Hepatitis C Treatment-Naive Patient | v | ||
| Direct-Acting Antiviral Agents: Regimens for the Interferon Failure Patient | v | ||
| Mechanisms of Virologic Failure with Direct-Acting Antivirals in Hepatitis C and Strategies for Retreatment | vi | ||
| Regimens for Cirrhotic Patients | vi | ||
| Current Management of Hepatitis C Virus: Regimens for Peri-Liver Transplant Patients | vi | ||
| Regimens for Patients Coinfected with Human Immunodeficiency Virus | vi | ||
| Next-Generation Regimens: The Future of Hepatitis C Virus Therapy | vii | ||
| CLINICS IN LIVER DISEASE | viii | ||
| FORTHCOMING ISSUES | viii | ||
| February 2016 | viii | ||
| May 2016 | viii | ||
| August 2016 | viii | ||
| RECENT ISSUES | viii | ||
| August 2015 | viii | ||
| May 2015 | viii | ||
| February 2015 | viii | ||
| Preface: Hepatitis C Therapy: Simple for the Patient, not so Simple for the Clinician | ix | ||
| Evaluation of Hepatitis C Patients in the Direct-Acting Antiviral Era | 591 | ||
| Key points | 591 | ||
| INTRODUCTION | 591 | ||
| SCREENING | 592 | ||
| CLINICAL EVALUATION | 593 | ||
| Pretreatment Investigations | 594 | ||
| Hepatitis C Virus Investigations | 594 | ||
| Other Investigations | 596 | ||
| Fibrosis Staging | 597 | ||
| DRUG-DRUG INTERACTIONS | 599 | ||
| COUNSELING | 599 | ||
| WHEN TO TREAT | 599 | ||
| SUMMARY | 601 | ||
| REFERENCES | 601 | ||
| Meet the Classes of Directly Acting Antiviral Agents | 605 | ||
| Key points | 605 | ||
| INTRODUCTION | 605 | ||
| THE HEPATITIS C VIRUS LIFE CYCLE | 606 | ||
| VIRAL ENTRY | 606 | ||
| VIRAL REPLICATION | 606 | ||
| THE ISSUE OF POLYMORPHISMS AND DRUG RESISTANCE | 608 | ||
| NS3/4A PROTEASE INHIBITORS | 610 | ||
| NS5A INHIBITORS | 610 | ||
| NS5B POLYMERASE INHIBITORS | 611 | ||
| Nucleoside/Nucleotide Analogue Inhibitors of Hepatitis C Virus NS5B Polymerase | 611 | ||
| NON-NUCLEOSIDE INHIBITORS OF HEPATITIS C VIRUS NS5B POLYMERASE | 612 | ||
| THE RATIONALE BEHIND COMBINATION THERAPY | 614 | ||
| SUMMARY | 614 | ||
| REFERENCES | 615 | ||
| Regimens for the Hepatitis C Treatment-Naive Patient | 619 | ||
| Key points | 619 | ||
| INTRODUCTION | 619 | ||
| TREATMENT IN NAIVE PATIENTS WITHOUT CIRRHOSIS | 620 | ||
| Hepatitis C Virus Genotype 1 | 620 | ||
| Hepatitis C Virus Genotype 2 | 622 | ||
| Hepatitis C Virus Genotype 3 | 622 | ||
| TREATMENT IN NAIVE PATIENTS WITH CIRRHOSIS | 623 | ||
| Hepatitis C Virus Genotype 1 | 623 | ||
| Hepatitis C Virus Genotype 2 | 623 | ||
| Hepatitis C Virus Genotype 3 | 624 | ||
| TREATMENT OF HEPATITIS C VIRUS GENOTYPE 4 INFECTION | 624 | ||
| TREATMENT OF HEPATITIS C VIRUS GENOTYPE 5 AND 6 INFECTION | 625 | ||
| FUTURE THERAPY | 625 | ||
| SUMMARY | 626 | ||
| REFERENCES | 626 | ||
| Direct-Acting Antiviral Agents | 629 | ||
| Key points | 629 | ||
| INTRODUCTION | 629 | ||
| HISTORY OF INTERFERON-CONTAINING REGIMENS | 629 | ||
| INTERFERON INTOLERABILITY | 630 | ||
| INTERFERON FAILURE | 631 | ||
| Currently Recommended Treatment Regimens for Interferon Failure Patients: A Review of the Evidence and Current Guidelines | 631 | ||
| GENOTYPES 1A AND 1B TREATMENT RECOMMENDATIONS | 634 | ||
| GENOTYPES 2 AND 3 TREATMENT RECOMMENDATIONS | 637 | ||
| GENOTYPES 4, 5, AND 6 TREATMENT RECOMMENDATIONS | 637 | ||
| SUMMARY | 638 | ||
| REFERENCES | 638 | ||
| Mechanisms of Virologic Failure with Direct-Acting Antivirals in Hepatitis C and Strategies for Retreatment | 641 | ||
| Key points | 641 | ||
| INTRODUCTION | 641 | ||
| MECHANISMS OF DIRECT-ACTING ANTIVIRAL DRUGS | 643 | ||
| Protease Inhibitors | 643 | ||
| NS5A Inhibitors | 644 | ||
| NS5B Non-nucleoside Polymerase Inhibitors | 644 | ||
| NS5B Nucleoside Polymerase Inhibitors | 644 | ||
| POTENTIAL FAILURE POPULATIONS | 644 | ||
| Mono–Direct-Acting Antiviral Therapy with Protease Inhibitor | 644 | ||
| Mono-Sofosbuvir Failures | 645 | ||
| All Oral Treatment Failures | 645 | ||
| MECHANISM OF NONRESPONSE TO ANTIVIRAL | 646 | ||
| Viral Factors | 646 | ||
| Host Factors | 648 | ||
| Altered Pharmacokinetics | 650 | ||
| Portosystemic Shunting and Cirrhosis | 650 | ||
| THERAPEUTIC OPTIONS FOR RETREATMENT OF DIRECT-ACTING ANTIVIRAL FAILURES | 651 | ||
| Clinical Trials Inclusive of Sofosbuvir Failures in Genotype 1 | 651 | ||
| Retreatment of Sofosbuvir Failures with Genotype 2 or 3 | 652 | ||
| Approach to Patients Requiring Retreatment | 653 | ||
| Cocktail Mixology for Hepatitis C Virus | 653 | ||
| SUMMARY | 653 | ||
| REFERENCES | 654 | ||
| Regimens for Cirrhotic Patients | 657 | ||
| Key points | 657 | ||
| TREATMENT OPTIONS: GENOTYPE 1 | 658 | ||
| Treatment Options for Genotype 1 Individuals Who Have Failed Previous Therapy | 659 | ||
| GENOTYPE 2 | 661 | ||
| GENOTYPE 3 | 661 | ||
| GENOTYPE 4 | 663 | ||
| GENOTYPES 5 AND 6 | 664 | ||
| REFERENCES | 665 | ||
| Current Management of Hepatitis C Virus | 669 | ||
| Key points | 669 | ||
| INTRODUCTION | 669 | ||
| HEPATITIS C VIRUS TREATMENT BEFORE LIVER TRANSPLANT TO ACHIEVE CURE | 671 | ||
| HEPATITIS C VIRUS TREATMENT BEFORE LIVER TRANSPLANT TO PREVENT HEPATITIS C VIRUS RECURRENCE | 677 | ||
| PREEMPTIVE HEPATITIS C VIRUS TREATMENT AFTER LIVER TRANSPLANT TO ACHIEVE CURE | 678 | ||
| HEPATITIS C VIRUS TREATMENT AFTER LIVER TRANSPLANT TO ACHIEVE CURE | 679 | ||
| Significant Fibrosis/Compensated Cirrhosis | 679 | ||
| Decompensated Cirrhosis | 681 | ||
| PRETRANSPLANT VERSUS POSTTRANSPLANT THERAPY: WHICH IS BETTER? | 682 | ||
| Wait-Listed Patients | 682 | ||
| Post–Liver Transplant Recipients | 682 | ||
| SUMMARY | 684 | ||
| REFERENCES | 684 | ||
| Regimens for Patients Coinfected with Human Immunodeficiency Virus | 689 | ||
| Key points | 689 | ||
| INTRODUCTION | 689 | ||
| Epidemiology and Natural History of Hepatitis C Virus in Patients with Human Immunodeficiency Virus 1 | 690 | ||
| Special Consideration in Evaluation of Patients Coinfected with Human Immunodeficiency Virus | 690 | ||
| Treatment of Hepatitis C Virus in Patients with Human Immunodeficiency Virus Using Interferon-containing Regimens | 691 | ||
| Antiretroviral Therapy Considerations and Drug-Drug Interactions | 692 | ||
| Current Regimens for Hepatitis C Virus Genotype 1 Treatment in Patients with Human Immunodeficiency Virus 1 | 693 | ||
| Nucleotide-based Hepatitis C Virus Treatment Regimens | 693 | ||
| Sofosbuvir plus interferon | 693 | ||
| Sofosbuvir plus RBV | 695 | ||
| Sofosbuvir-antiretroviral drug interactions | 696 | ||
| Sofosbuvir plus an NS5A inhibitor | 696 | ||
| NS5A inhibitor drug interactions and implications for sofosbuvir/NS5A regimens | 698 | ||
| Sofosbuvir plus an NS3 protease inhibitor | 699 | ||
| NS3 protease inhibitor–based regimens | 699 | ||
| Human Immunodeficiency Virus Control During Direct-acting Antiviral Therapy | 701 | ||
| SUMMARY | 701 | ||
| REFERENCES | 702 | ||
| Next-Generation Regimens | 707 | ||
| Key points | 707 | ||
| INTRODUCTION | 707 | ||
| LIMITATIONS OF PAST REGIMENS | 707 | ||
| PHASE III TRIALS | 708 | ||
| Daclatasvir/Asunaprevir/Beclabuvir | 708 | ||
| Daclatasvir/Sofosbuvir | 708 | ||
| PHASE II TRIALS | 709 | ||
| Grazoprevir (MK-5172)/Elbasvir (MK-8742) | 709 | ||
| GS-5816/Sofosbuvir | 710 | ||
| ACH-3102 | 710 | ||
| PHASE I | 710 | ||
| ABT-493/ABT-530 | 710 | ||
| MK-3682 (Formally IDX21437) | 710 | ||
| PRECLINICAL AGENTS | 713 | ||
| MK-8408 | 713 | ||
| HOST TARGETED AGENTS | 713 | ||
| MIRAVIRSEN | 713 | ||
| RG-101 | 713 | ||
| FUTURE FRONTIERS | 714 | ||
| REFERENCES | 714 |